CoChat
Sign Up
Cited by 667Atrial Fibrillation Management and OutcomesCardiac Arrhythmias and TreatmentsCardiac pacing and defibrillation studies

The DOI matches its Crossref record; 29 of the 31 references it cites were found in a registry or an index.

Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2): A Randomized Trial

Open access
Morillo, Carlos A., Verma, Atul, Connolly, Stuart J., Kuck, Karl H., Nair, Girish M., Champagne, Jean, Sterns, Laurence D., Beresh, Heather, Healey, Jeffrey S., Natale, Andrea, RAAFT-2 Investigators·2014·JAMA
DOI 10.1001/jama.2014.467
Open this paper in CoChat — free accountOpen PDF

Abstract

IMPORTANCE: Atrial fibrillation (AF) is the most common rhythm disorder seen in clinical practice. Antiarrhythmic drugs are effective for reduction of recurrence in patients with symptomatic paroxysmal AF. Radiofrequency ablation is an accepted therapy in patients for whom antiarrhythmic drugs have failed; however, its role as a first-line therapy needs further investigation. OBJECTIVE: To compare radiofrequency ablation with antiarrhythmic drugs (standard therapy) in treating patients with paroxysmal AF as a first-line therapy. DESIGN, SETTING, AND PATIENTS: A randomized clinical trial involving 127 treatment-naive patients with paroxysmal AF were randomized at 16 centers in Europe and North America to received either antiarrhythmic therapy or ablation. The first patient was enrolled July 27, 2006; the last patient, January 29, 2010. The last follow-up was February 16, 2012. INTERVENTIONS: Sixty-one patients in the antiarrhythmic drug group and 66 in the radiofrequency ablation group were followed up for 24 months. MAIN OUTCOMES AND MEASURES: The time to the first documented atrial tachyarrhythmia of more than 30 seconds (symptomatic or asymptomatic AF, atrial flutter, or atrial tachycardia), detected by either scheduled or unscheduled electrocardiogram, Holter, transtelephonic monitor, or rhythm strip, was the primary outcome. Secondary outcomes included symptomatic recurrences of atrial tachyarrhythmias and quality of life measures assessed by the EQ-5D tool. RESULTS: Forty-four patients (72.1%) in the antiarrhythmic group and in 36 patients (54.5%) in the ablation group experienced the primary efficacy outcome (hazard ratio [HR], 0.56 [95% CI, 0.35-0.90]; P = .02). For the secondary outcomes, 59% in the drug group and 47% in the ablation group experienced the first recurrence of symptomatic AF, atrial flutter, atrial tachycardia (HR, 0.56 [95% CI, 0.33-0.95]; P = .03). No deaths or strokes were reported in either group; 4 cases of cardiac tamponade were reported in the ablation group. In the standard treatment group, 26 patients (43%) underwent ablation after 1-year. Quality of life was moderately impaired at baseline in both groups and improved at the 1 year follow-up. However, improvement was not significantly different among groups. CONCLUSIONS AND RELEVANCE: Among patients with paroxysmal AF without previous antiarrhythmic drug treatment, radiofrequency ablation compared with antiarrhythmic drugs resulted in a lower rate of recurrent atrial tachyarrhythmias at 2 years. However, recurrence was frequent in both groups. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00392054.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2014.467

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. EuroQol Group, 2007, EQ-5D Value Sets: Inventory, Comparative Eview and User Guide

Cited by

Sorted by citations

Items 301–400 of 667

Related

See all

Metadata

Authors
Morillo, C. A., Verma, A., Connolly, S. J., Kuck, K. H., Nair, G. M., Champagne, J., Sterns, L. D., Beresh, H., Healey, J. S., Natale, A., & RAAFT-2 Investigators
Affiliations
  • Population Health Research Institute (CA)
  • Southlake Regional Health Center (CA)
  • Asklepios Klinik St Georg, Hamburg, Germany
  • Ottawa Heart Institute (CA)
  • Université Laval (CA)
  • Victoria Cardiac Arrhythmia Trials Inc, Victoria, Canada
  • McMaster University, Population Health Research Institute, Hamilton Health Sciences, Hamilton, Canada
  • St David's Medical Center (US)
Corresponding author
Morillo, Carlos A.
ORCID
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2014-02-19
Volume
311
Issue
7
Pages
692
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.2014.467
OpenAlex
W2125891322
Cited by
667
References
31
Citations by year
2026: 23 · 2025: 50 · 2024: 58 · 2023: 44 · 2022: 60 · 2021: 68 · 2020: 63 · 2019: 47 · 2018: 45 · 2017: 56 · 2016: 63 · 2015: 48 · 2014: 37
FWCI
46.73
Type
journal article
Language
en
Open access
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Funders
Biosense Webster
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
Keywords
paroxysmal atrial fibrillation, radiofrequency catheter ablation, antiarrhythmic drugs, first-line therapy, atrial tachyarrhythmia recurrence, atrial flutter, atrial tachycardia, quality of life, treatment-naive patients, bleeding risk
MeSH terms
Adult, Aged, Anti-Arrhythmia Agents, Atrial Fibrillation, Atrial Flutter, Female, Heart Atria, Humans, Male, Middle Aged, Recurrence, Tachycardia, Treatment Outcome, Catheter Ablation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review